Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses: an economic analysis and budget impact analysis

Membe SK, Coyle D, Husereau D, Cimon K, Tinmouth A, Normandin S
Record ID 32010001777
English
Authors' recommendations: Octaplas is associated with reduced disease burden at a higher cost than standard FP or FFP The cost-effectiveness of Octaplas will be determined by a decision maker’s willingness to pay for a QALY. The incremental cost per QALY results from low transfusion-related risks for FP or FFP engineered by advances in the safety measures of blood transfusion, such as testing, donor screening, and deferral. Also, due to the average age (65 years) of plasma recipients and the poor short-term prognosis of recipients, projected benefits of Octaplas are reduced.Switching to Octaplas provides absolute benefits to the health care system, as it increases the volume of much-needed IVIg and albumin. However, overall, in relative terms, the health care system incurs a net loss, as it could purchase the added volume of IVIg and albumin at lower total cost from its current suppliers.
Details
Project Status: Completed
Year Published: 2009
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Blood-Borne Pathogens
  • Plasma
  • Plasma Exchange
  • Solvents
  • Virus Diseases
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.